ATAD1 and prostate cancer: Previous trials of proteasome inhibitors in unselected patients with prostate cancer have shown activity in a subset of patients, consistent with the possibility that this subset was enriched for patients with ATAD1-null tumors (Papandreou et al., 2004; Naik et al., 2018; Morris et al., 2007).